# Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

> **NCT06923345** · PHASE2 · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 80 (estimated)

## Conditions studied

- Rectal Cancer
- Neoadjuvant Therapies
- Immune Checkpoint Therapy
- Radiotherapy

## Interventions

- **COMBINATION_PRODUCT:** Reduced CTV
- **COMBINATION_PRODUCT:** Conventional CTV

## Key facts

- **NCT ID:** NCT06923345
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923345, "Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06923345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*